Brook Byers

Brook Byers has been a venture capital investor since 1972. He has been closely involved with founders to help build…

Brook Byers

Founder

Brook Byers has been a venture capital investor since 1972. He has been closely involved with founders to help build more than 60 new technology-based companies. He formed the first life sciences practice group in the venture capital profession in 1984 and led Kleiner Perkins to become a premier venture capital firm in the life sciences, healthcare and biotechnology sectors.

Brook was the founding president and then chairman of four biotechnology companies that were incubated in Kleiner Perkins’ offices and went on to become public companies with an aggregate market value of more than US$8 billion. He currently serves on the board of directors of Arsenal Bio, Octave Bio, Newsela and Verana Health. Brook serves on the board of the Stanford Center for BioDesign and is a Lifetime Board Member of the University of California San Francisco Medical Center. He served on the Board of Trustees of Stanford University, the Asian Art Museum in San Francisco and the Georgia Tech Advisory Board. He was also a founder of TechNet.

Raised in Atlanta, Georgia, Brook graduated with a bachelor’s degree in electrical engineering from Georgia Tech and received an M.B.A. from Stanford University. He received an Honorary PhD from Georgia Tech.

Nonprofit Boards
— UCSF Foundation Board – Lifetime Director
— UCSF Innovation and Partnerships Board
— Stanford Medicine Advisory Board
— Stanford BioDesign Advisory Board
— New Schools Venture Fund Board

Companies Backed
Programmable cell therapy
Since 2019
Authentic, trusted content
Since 2015
Disruptive cell-based therapies
Alumni (Acquired by Gilead Sciences)
Molecular diagnostics
Alumni (Myriad Genetics)
Inspiring the world through play
Alumni
Driving advancement in cancer genomics
Alumni (Acquired by Roche)
Delivering on the promise of biotechnology
Alumni (Acquired by Roche)
Genetic research and cancer detection
Alumni (Acquired by Exact Sciences)
Addressing unmet clinical need in ophthamology
Alumni (Acquired by Allergan)
Life-improving vision technologies
Alumni (Acquired by Abbott)
The world’s most advanced sequencing systems
Alumni (PACB)
Pioneering global diagnostics
Alumni (VCYT)